Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCEPT: Cemiplimab monotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma
2025-523633-25-00Phase 2Authorised
- Sponsor
- GONO Foundation
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by GONO Foundation. Primary endpoint: Proportion of patients who do not require surgery at one year (ITT). Planned start Jul 2026; status: authorised.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on 2025-523633-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523633-25-00.